The FDA has updated echo monitoring requirements for eligible patients in the maintenance phase
For adults with symptomatic NYHA Class II–III obstructive HCM
A DIFFERENCE YOU CAN SEE *
AND PATIENTS CAN FEEL†
* | Echocardiogram assessment of postexercise LVOT gradient.1 |
† | Evaluation of symptoms, via NYHA classification.1 |
‡ | Symptoms include effort-related dyspnea or chest pain, and occasionally other exertional symptoms (eg, syncope, near syncope) that are attributed to LVOT obstruction and interfere with everyday activity or quality of life despite beta blocker or nondihydropyridine calcium channel blocker.2 |
CAMZYOS
Efficacy & Safety
Explore pivotal trial and long-term
efficacy and safety data.1
CAMZYOS
Dosing & Administration
Review important dosing and treatment recommendations.1
Start and
Maintain Patients
Resources for appropriate
patients on CAMZYOS.
1L=first line; ACC=American College of Cardiology; AHA=American Heart Association; CMI=cardiac myosin inhibitor; FDA=US Food and Drug Administration; HCM=hypertrophic cardiomyopathy; LVOT=left ventricular outflow tract; MS=multisociety; NYHA=New York Heart Association.
References:
- CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
- Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e1311. doi:10.1161/CIR.0000000000001250